| Code | CSB-RA011087MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Veligrotug, targeting the insulin-like growth factor 1 receptor (IGF1R). IGF1R is a transmembrane tyrosine kinase receptor that plays a critical role in cellular growth, proliferation, differentiation, and survival through the IGF signaling pathway. Upon ligand binding, IGF1R undergoes autophosphorylation and activates downstream signaling cascades including the PI3K/AKT and MAPK pathways. Aberrant IGF1R signaling has been implicated in various malignancies, including colorectal cancer, breast cancer, and sarcomas, where it contributes to tumor growth, metastasis, and resistance to conventional therapies.
Veligrotug is a fully humanized monoclonal antibody that was investigated in clinical trials for its potential to inhibit IGF1R-mediated signaling in cancer treatment. This biosimilar antibody provides researchers with a valuable tool for investigating IGF1R biology, studying receptor-ligand interactions, exploring mechanisms of oncogenic transformation, and evaluating therapeutic strategies targeting the IGF axis in preclinical models. It serves as an important reagent for cancer biology research and drug development studies.
There are currently no reviews for this product.